Show simple item record

dc.contributor.authorBerger, Ola
dc.contributor.authorGrønberg, Bjørn Henning
dc.contributor.authorLoge, Jon Håvard
dc.contributor.authorKaasa, Stein
dc.contributor.authorSand, Kari
dc.date.accessioned2019-02-21T08:13:39Z
dc.date.available2019-02-21T08:13:39Z
dc.date.created2018-06-18T14:33:45Z
dc.date.issued2018
dc.identifier.citationBMC Cancer. 2018, 18:381 1-11.nb_NO
dc.identifier.issn1471-2407
dc.identifier.urihttp://hdl.handle.net/11250/2586629
dc.description.abstractBackground Knowledge about disease and treatment is necessary before patients can consent to treatment. One of the few established instruments for evaluating whether sufficient information has been provided, is the EORTC QLQ-INFO25 questionnaire which was developed to measure how patients perceive information. The aim of this study was to investigate whether cancer patients’ level of knowledge about their disease and treatment was associated with their perception of and satisfaction with the information. Methods Breast cancer patients referred for adjuvant chemotherapy and prostate cancer patients referred for curative radiotherapy were included. Level of knowledge about their disease and treatment was measured using study-specific questionnaires. Patients’ perception of and satisfaction with the received information was assessed using EORTC QLQ-INFO25. Assessments were done before the first consultation with an oncologist (T1), after the consultation (T2) and 8 weeks after start of treatment (T3). Results Ninety eight patients were enrolled. Patients with higher education, daily Internet access and in paid employment had the highest baseline knowledge scores. The mean knowledge score increased significantly (T1: 16.4; T2: 20.8; T3: 21.3; p < 0.001.). During the same period, the patients reported on the INFO25 a significant, positive increase in how much information they had received, and that they were more satisfied with the information. Conclusions Patients’ knowledge increased significantly during the study period, and they reported that they felt better informed and were more satisfied with the information, suggesting that EORTC QLQ-INFO25 might be used to evaluate cancer patients’ level of knowledge about their disease and treatment.nb_NO
dc.language.isoengnb_NO
dc.publisherBMC (part of Springer Nature)nb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleCancer patients' knowledge about their disease and treatment before, during and after treatment: a prospective, longitudinal studynb_NO
dc.title.alternativeCancer patients' knowledge about their disease and treatment before, during and after treatment: a prospective, longitudinal studynb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber1-11nb_NO
dc.source.volume18:381nb_NO
dc.source.journalBMC Cancernb_NO
dc.identifier.doi10.1186/s12885-018-4164-5
dc.identifier.cristin1591963
dc.description.localcode© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/)nb_NO
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal